$BIOLQ
BIOLASE, INC

2013 Q4 Form 10-K Financial Statement

#000156459014000856 Filed on March 17, 2014

View on sec.gov

Income Statement

Concept 2013 Q4 2013 2012 Q4
Revenue $15.24M $56.43M $19.08M
YoY Change -20.13% -1.61% 44.98%
Cost Of Revenue $9.030M $34.90M $10.19M
YoY Change -11.38% 13.03% 33.9%
Gross Profit $6.220M $21.53M $8.890M
YoY Change -30.03% -18.69% 60.18%
Gross Profit Margin 40.81% 38.15% 46.59%
Selling, General & Admin $7.200M $28.06M $6.670M
YoY Change 7.95% 15.35% 3.89%
% of Gross Profit 115.76% 130.33% 75.03%
Research & Development $1.040M $4.029M $1.030M
YoY Change 0.97% -13.98% -3.74%
% of Gross Profit 16.72% 18.71% 11.59%
Depreciation & Amortization $160.0K $601.0K $140.0K
YoY Change 14.29% 17.15% 0.0%
% of Gross Profit 2.57% 2.79% 1.57%
Operating Expenses $8.240M $32.53M $7.700M
YoY Change 7.01% 12.12% 2.8%
Operating Profit -$2.020M -$11.00M $1.190M
YoY Change -269.75% 334.45% -161.34%
Interest Expense -$190.0K -$600.0K -$140.0K
YoY Change 35.71% -351.05% 75.0%
% of Operating Profit -11.76%
Other Income/Expense, Net -$650.0K
YoY Change 57.0%
Pretax Income -$2.220M -$11.65M $1.060M
YoY Change -309.43% 295.45% -152.48%
Income Tax $20.00K -$164.0K $10.00K
% Of Pretax Income 0.94%
Net Earnings -$2.230M -$11.48M $1.040M
YoY Change -314.42% 275.72% -151.23%
Net Earnings / Revenue -14.63% -20.35% 5.45%
Basic Earnings Per Share -$0.35
Diluted Earnings Per Share -$329.4K -$0.35 $149.2K
COMMON SHARES
Basic Shares Outstanding 32.77M 31.12M shares
Diluted Shares Outstanding 32.77M

Balance Sheet

Concept 2013 Q4 2013 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.440M $1.440M $2.540M
YoY Change -43.31% -43.31% -23.26%
Cash & Equivalents $1.440M $1.440M $2.543M
Short-Term Investments
Other Short-Term Assets $1.910M $1.910M $1.550M
YoY Change 23.23% 23.23% -14.36%
Inventory $11.38M $11.38M $11.14M
Prepaid Expenses
Receivables $11.13M $10.96M $11.68M
Other Receivables $85.00K $170.0K $179.0K
Total Short-Term Assets $25.85M $25.85M $26.92M
YoY Change -3.95% -3.97% 6.28%
LONG-TERM ASSETS
Property, Plant & Equipment $1.826M $1.830M $1.509M
YoY Change 21.01% 21.19% 31.45%
Goodwill $2.926M $2.926M
YoY Change 0.0% 0.0%
Intangibles $183.0K $300.0K
YoY Change -39.0% 41.51%
Long-Term Investments
YoY Change
Other Assets $249.0K $250.0K $305.0K
YoY Change -18.36% -21.88% 63.1%
Total Long-Term Assets $5.184M $5.190M $5.056M
YoY Change 2.53% 2.77% 12.83%
TOTAL ASSETS
Total Short-Term Assets $25.85M $25.85M $26.92M
Total Long-Term Assets $5.184M $5.190M $5.056M
Total Assets $31.04M $31.04M $31.97M
YoY Change -2.92% -2.91% 7.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.560M $8.560M $7.663M
YoY Change 11.71% 11.75% -1.81%
Accrued Expenses $4.997M $4.330M $6.267M
YoY Change -20.26% -17.99% 1.46%
Deferred Revenue
YoY Change
Short-Term Debt $4.630M $4.630M $1.640M
YoY Change 182.32% 182.32%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.94M $21.94M $19.38M
YoY Change 13.23% 13.21% 19.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $138.0K
YoY Change -100.0% -100.0% -59.05%
Total Long-Term Liabilities $0.00 $0.00 $138.0K
YoY Change -100.0% -100.0% -59.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.94M $21.94M $19.38M
Total Long-Term Liabilities $0.00 $0.00 $138.0K
Total Liabilities $22.56M $22.56M $20.18M
YoY Change 11.78% 11.79% 17.06%
SHAREHOLDERS EQUITY
Retained Earnings -$123.8M -$112.3M
YoY Change 10.23% 2.8%
Common Stock $148.9M $34.00K
YoY Change 437852.94% -99.98%
Preferred Stock
YoY Change
Treasury Stock (at cost) $16.40M $16.40M
YoY Change 0.0% 0.0%
Treasury Stock Shares $1.964M $1.964M
Shareholders Equity $8.481M $8.480M $11.79M
YoY Change
Total Liabilities & Shareholders Equity $31.04M $31.04M $31.97M
YoY Change -2.92% -2.91% 7.27%

Cashflow Statement

Concept 2013 Q4 2013 2012 Q4
OPERATING ACTIVITIES
Net Income -$2.230M -$11.48M $1.040M
YoY Change -314.42% 275.72% -151.23%
Depreciation, Depletion And Amortization $160.0K $601.0K $140.0K
YoY Change 14.29% 17.15% 0.0%
Cash From Operating Activities -$2.210M -$9.296M $1.900M
YoY Change -216.32% 458.65% -194.06%
INVESTING ACTIVITIES
Capital Expenditures -$220.0K $675.0K -$90.00K
YoY Change 144.44% -16.46% -35.71%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$10.00K -$10.00K
YoY Change -100.0% -109.09%
Cash From Investing Activities -$220.0K -$685.0K -$110.0K
YoY Change 100.0% -1.86% -21.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.201M
YoY Change 2113.19%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -310.0K 8.847M -550.0K
YoY Change -43.64% 467.48% 129.17%
NET CHANGE
Cash From Operating Activities -2.210M -9.296M 1.900M
Cash From Investing Activities -220.0K -685.0K -110.0K
Cash From Financing Activities -310.0K 8.847M -550.0K
Net Change In Cash -2.740M -1.134M 1.900M
YoY Change -244.21% 41.22% -179.17%
FREE CASH FLOW
Cash From Operating Activities -$2.210M -$9.296M $1.900M
Capital Expenditures -$220.0K $675.0K -$90.00K
Free Cash Flow -$1.990M -$9.971M $1.990M
YoY Change -200.0% 303.36% -205.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
138000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1552000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2543000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4997000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6267000
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Liabilities
Liabilities
22557000
CY2012Q4 us-gaap Liabilities
Liabilities
20179000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7663000
CY2012Q4 us-gaap Inventory Net
InventoryNet
11142000
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
183000
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
300000
CY2012Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
16000
CY2013Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
4633000
CY2012Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1637000
CY2012Q4 us-gaap Customer Deposits Current
CustomerDepositsCurrent
582000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3226000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19375000
CY2013Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
617000
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
663000
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
148866000
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-320000
CY2013 biol Excise Tax
ExciseTax
438000
CY2012 biol Excise Tax
ExciseTax
CY2013Q4 us-gaap Assets
Assets
31038000
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37407545
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1440000
CY2013Q2 dei Entity Public Float
EntityPublicFloat
96933145
CY2012Q4 us-gaap Goodwill
Goodwill
2926000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
249000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
26917000
CY2011 us-gaap Operating Expenses
OperatingExpenses
25322000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4029000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9377000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1826000
CY2013Q4 us-gaap Inventory Net
InventoryNet
11378000
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11680000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1509000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
25854000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1909000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11127000
CY2013 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-50000
CY2012 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-175000
CY2011 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-88000
CY2012 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-239000
CY2013 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
18682000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8075000
CY2011 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-305000
CY2011 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-393000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4684000
CY2013 us-gaap Operating Expenses
OperatingExpenses
32526000
CY2012 us-gaap Operating Expenses
OperatingExpenses
29009000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-2531000
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
-3047000
CY2011 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
74000
CY2011 us-gaap Inventory Write Down
InventoryWriteDown
392000
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
695000
CY2013Q4 us-gaap Goodwill
Goodwill
2926000
CY2012Q4 us-gaap Assets
Assets
31973000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8560000
CY2013Q4 us-gaap Customer Deposits Current
CustomerDepositsCurrent
285000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
305000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3464000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21939000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
1600000
CY2012 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
91000
CY2011 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
99000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
1609000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
34000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112268000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123750000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
8481000
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
573000
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37336000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35372000
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4311000
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32581000
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32581000
CY2012 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31975000
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31975000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-274000
CY2011 biol Excise Tax
ExciseTax
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-10996000
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-4004000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-4486000
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-414000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-650000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
111000
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
89000
CY2013 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-600000
CY2013Q4 biol Stockholders Equity Excluding Treasury Stock
StockholdersEquityExcludingTreasuryStock
24880000
CY2012Q4 biol Stockholders Equity Excluding Treasury Stock
StockholdersEquityExcludingTreasuryStock
28193000
CY2013Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1096000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
140747000
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
16399000
CY2012Q4 us-gaap Treasury Stock Value
TreasuryStockValue
16399000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
11794000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31038000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31973000
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
304000
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33248000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31284000
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1964000
CY2012Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1964000
CY2013 biol Products And Services Revenue
ProductsAndServicesRevenue
56186000
CY2012 biol Products And Services Revenue
ProductsAndServicesRevenue
57191000
CY2011 biol Products And Services Revenue
ProductsAndServicesRevenue
48419000
CY2012 biol License Fees And Royalty Revenue
LicenseFeesAndRoyaltyRevenue
165000
CY2011 biol License Fees And Royalty Revenue
LicenseFeesAndRoyaltyRevenue
439000
CY2011 us-gaap Sales Revenue Net
SalesRevenueNet
48858000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-11646000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2945000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4397000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-164000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-11482000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-3056000
CY2013 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
46000
CY2012 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
40000
CY2011 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-36000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11436000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3016000
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4522000
CY2011 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2011 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2011 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30575000
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1244000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1528000
CY2011 biol Adjustments To Additional Paid In Capital Non Employee Equity Instruments
AdjustmentsToAdditionalPaidInCapitalNonEmployeeEquityInstruments
273000
CY2011 biol Adjustments To Additional Paid In Capital Fair Value Of Other Compensation
AdjustmentsToAdditionalPaidInCapitalFairValueOfOtherCompensation
250000
CY2011 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17223000
CY2011 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
268000
CY2011 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30575000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1600000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y7M24D
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y8M12D
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y1M24D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.84
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.05
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0104
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0077
CY2011 biol Adjustments To Additional Paid In Capital Warrant Repurchased
AdjustmentsToAdditionalPaidInCapitalWarrantRepurchased
130000
CY2011 biol Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
18000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
12569000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
455000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1600000
CY2012 biol Adjustments To Additional Paid In Capital Non Employee Equity Instruments
AdjustmentsToAdditionalPaidInCapitalNonEmployeeEquityInstruments
23000
CY2012 biol Adjustments To Additional Paid In Capital Fair Value Of Other Compensation
AdjustmentsToAdditionalPaidInCapitalFairValueOfOtherCompensation
250000
CY2012 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
235000
CY2012 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
142000
CY2012 biol Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
6000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
709000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1609000
CY2013 biol Adjustments To Additional Paid In Capital Non Employee Equity Instruments
AdjustmentsToAdditionalPaidInCapitalNonEmployeeEquityInstruments
106000
CY2013 biol Adjustments To Additional Paid In Capital Fair Value Of Other Compensation
AdjustmentsToAdditionalPaidInCapitalFairValueOfOtherCompensation
250000
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5169000
CY2013 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
280000
CY2013 biol Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
601000
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
513000
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-15000
CY2011 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-36000
CY2013 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
291000
CY2012 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
241000
CY2013 us-gaap Inventory Write Down
InventoryWriteDown
1132000
CY2012 us-gaap Inventory Write Down
InventoryWriteDown
330000
CY2013 biol Amortization Of Discounts On Lines Of Credit
AmortizationOfDiscountsOnLinesOfCredit
179000
CY2012 biol Amortization Of Discounts On Lines Of Credit
AmortizationOfDiscountsOnLinesOfCredit
43000
CY2011 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
78000
CY2013 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
197000
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
1528000
CY2013 biol Other Equity Instruments Compensation
OtherEquityInstrumentsCompensation
106000
CY2012 biol Other Equity Instruments Compensation
OtherEquityInstrumentsCompensation
23000
CY2011 biol Other Equity Instruments Compensation
OtherEquityInstrumentsCompensation
273000
CY2013 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-250000
CY2012 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-250000
CY2011 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-250000
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-30000
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
61000
CY2011 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
53000
CY2013 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
27000
CY2012 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
19000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-264000
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3222000
CY2011 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5642000
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1436000
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
160000
CY2011 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4716000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-56000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-450000
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
552000
CY2013 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-297000
CY2012 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
417000
CY2011 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-5711000
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-999000
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-347000
CY2011 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4230000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
236000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1068000
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
79000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1898000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
502000
CY2012 us-gaap Advertising Expense
AdvertisingExpense
907000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9296000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1664000
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13320000
CY2012 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
16600000
CY2013 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
32104000
CY2012 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
14963000
CY2011 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2700000
CY2013 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
57000
CY2012 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
304000
CY2012 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6000
CY2011 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
18000
CY2011 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
130000
CY2011Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
2218000
CY2010Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
2725000
CY2013 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
475000
CY2012 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1705000
CY2011 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1586000
CY2013 us-gaap Product Warranty Expense
ProductWarrantyExpense
1078000
CY2012 us-gaap Product Warranty Expense
ProductWarrantyExpense
2224000
CY2011 us-gaap Product Warranty Expense
ProductWarrantyExpense
2093000
CY2013Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1096000
CY2013Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
675000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
808000
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
428000
CY2012 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
124000
CY2013 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10000
CY2012 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
14000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-685000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-698000
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-428000
CY2013 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
35100000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5201000
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17223000
CY2012 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
235000
CY2011 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
268000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
707000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8847000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1559000
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15387000
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
31000
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
39000
CY2011 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-26000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1103000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-764000
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1613000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3307000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1694000
CY2013 us-gaap Interest Paid
InterestPaid
220000
CY2012 us-gaap Interest Paid
InterestPaid
88000
CY2011 us-gaap Interest Paid
InterestPaid
80000
CY2013 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
47000
CY2012 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
62000
CY2011 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
44000
CY2012 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
200000
CY2013Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1727000
CY2013Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6557000
CY2012Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
7836000
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6518000
CY2012Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1318000
CY2012Q4 us-gaap Land
Land
191000
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;margin-right:0%;text-indent:0%;font-size:10pt;font-family:Times New Roman;"><font style="font-weight:bold;font-style:italic;;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </font></p><p style="margin-bottom:0pt;margin-top:6pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory and deferred taxes, as well as estimates for accrued warranty expenses, indefinite-lived intangible assets and the ability of goodwill to be realized, revenue deferrals for multiple element arrangements, effects of stock-based compensation and warrants, contingent liabilities and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates. </font></p></div>
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;margin-right:0%;text-indent:0%;font-size:10pt;font-family:Times New Roman;"><font style="font-style:italic;;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Concentration of credit risk, interest rate risk and foreign currency exchange rate risk </font></p><p style="margin-bottom:0pt;margin-top:6pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, restricted cash, and trade accounts receivable. The Company maintains its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers&#8217; financial condition and maintains relationships with the Company&#8217;s customers which allow management to monitor current changes in business operations respond as needed. The Company does not, generally, require customers to provide collateral before it sells them products; however it</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> has required certain distributors to make prepayments for significant purchases of products. For the years ended December&#160;31, 2013, 2012, and 2011, worldwide sales to the Company&#8217;s largest distributor, Henry Schein, Inc. (&#8220;HSIC&#8221;), accounted for approximately 5%, 3%, and 19%, respectively, of our net sales. </font></p><p style="margin-bottom:0pt;margin-top:12pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">Substantially all of the Company&#8217;s revenue is denominated in U.S.&#160;dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company&#8217;s foreign currency expenditures primarily consist of the cost of maintaining offices, including the facilities, consulting services and employee-related costs. To date, the Company has not entered into any hedging contracts. Future fluctuations in the value of the U.S.&#160;dollar may, however, affect the price competitiveness of the Company&#8217;s products outside the United States. </font></p><p style="margin-bottom:0pt;margin-top:12pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">Outstanding balances on the Company&#8217;s lines of credit expose it to variable interest rate risks associated with fluctuations in the daily prime rate and LIBOR rate. Under the Company&#8217;s current policies, it does not use interest rate derivative instruments to manage exposure to interest rate changes. An increase in the daily prime rate or LIBOR rate would increase the interest expense the Company must pay.</font></p></div>
CY2013 biol Recent Accounting Pronouncements Policy Text B Lock
RecentAccountingPronouncementsPolicyTextBLock
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;margin-right:0%;text-indent:0%;font-size:10pt;font-family:Times New Roman;"><font style="font-weight:bold;font-style:italic;;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </font></p><p style="margin-bottom:0pt;margin-top:6pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">Changes to U.S. GAAP are established by the FASB in the form of accounting standards updates (&#8220;ASU&#8217;s&#8221;) to the FASB&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;). </font></p><p style="margin-bottom:0pt;margin-top:12pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">The Company considers the applicability and impact of all ASU&#8217;s. ASU&#8217;s not listed below were assessed and determined to not be applicable or are expected to have minimal impact on our consolidated financial position and results of operations. </font></p></div>
CY2013 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.05
CY2012 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.03
CY2011 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.19
CY2013Q4 biol Working Capital
WorkingCapital
3900000
CY2013Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
3400000
CY2013 biol Number Revolving Credit Facility Agreements
NumberRevolvingCreditFacilityAgreements
2
CY2014Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
1300000
CY2012Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1699000
CY2012Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
CY2011Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6039000
CY2013Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3094000
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4017000
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1949000
CY2012Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5176000
CY2012Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1699000
CY2011Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
2218000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1609000
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1528000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.97
CY2013 biol Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend
0.00
CY2012 biol Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend
0.00
CY2011 biol Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend
0.00
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0153
CY2013 us-gaap Depreciation
Depreciation
484000
CY2012 us-gaap Depreciation
Depreciation
377000
CY2011 us-gaap Depreciation
Depreciation
565000
CY2013Q4 biol Undelivered Elements Training Installation And Product And Support Services
UndeliveredElementsTrainingInstallationAndProductAndSupportServices
1823000
CY2012Q4 biol Undelivered Elements Training Installation And Product And Support Services
UndeliveredElementsTrainingInstallationAndProductAndSupportServices
1723000
CY2013 us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
110000
CY2012 us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
110000
CY2013Q4 biol Undelivered Elements Extended Warranty
UndeliveredElementsExtendedWarranty
1600000
CY2012Q4 biol Undelivered Elements Extended Warranty
UndeliveredElementsExtendedWarranty
1500000
CY2013 us-gaap Licenses Revenue
LicensesRevenue
0
CY2012 us-gaap Licenses Revenue
LicensesRevenue
0
CY2011 us-gaap Licenses Revenue
LicensesRevenue
64000
CY2013 us-gaap Advertising Expense
AdvertisingExpense
1500000
CY2011 us-gaap Advertising Expense
AdvertisingExpense
444000
CY2013 biol Share Based Compensation Net Impact On Earning Per Share Diluted
ShareBasedCompensationNetImpactOnEarningPerShareDiluted
0.05
CY2012 biol Share Based Compensation Net Impact On Earning Per Share Diluted
ShareBasedCompensationNetImpactOnEarningPerShareDiluted
0.05
CY2011 biol Share Based Compensation Net Impact On Earning Per Share Diluted
ShareBasedCompensationNetImpactOnEarningPerShareDiluted
0.05
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2700000
CY2012Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1900000
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4713000
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4626000
CY2013Q4 biol Trade Accounts Receivables
TradeAccountsReceivables
10960000
CY2012Q4 biol Trade Accounts Receivables
TradeAccountsReceivables
11456000
CY2013Q4 biol Royalty Revenues Receivable
RoyaltyRevenuesReceivable
82000
CY2012Q4 biol Royalty Revenues Receivable
RoyaltyRevenuesReceivable
45000
CY2013Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
85000
CY2012Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
179000
CY2013Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
8598000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6971000
CY2013Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1627000
CY2013Q4 us-gaap Land
Land
199000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2326000
CY2013Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
322000
CY2012Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
763000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
912000
CY2013Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
428000
CY2012Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
751000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
341000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
226000
CY2013Q4 biol Undelivered Elements Extended Warranty Current
UndeliveredElementsExtendedWarrantyCurrent
1642000
CY2012Q4 biol Undelivered Elements Extended Warranty Current
UndeliveredElementsExtendedWarrantyCurrent
1506000
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
3465000
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
3229000
CY2013Q4 biol Undelivered Elements Extended Warranty Noncurrent
UndeliveredElementsExtendedWarrantyNoncurrent
1000
CY2012Q4 biol Undelivered Elements Extended Warranty Noncurrent
UndeliveredElementsExtendedWarrantyNoncurrent
3000
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
573000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
204000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
304000
CY2013Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2800000
CY2012Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1900000
CY2013 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
183000
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2500000
CY2012 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
300000
CY2013 biol Indefinite Lived Intangible Assets Useful Life
IndefiniteLivedIntangibleAssetsUsefulLife
Indefinite life
CY2013Q4 us-gaap Goodwill Gross
GoodwillGross
2926000
CY2012Q4 us-gaap Goodwill Gross
GoodwillGross
2926000
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
117000
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
136000
CY2011 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
130000
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
69000
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
62000
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
52000
CY2012Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
8000000
CY2013Q4 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
4600000
CY2013 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2014-05-01
CY2013 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
197000
CY2012 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
91000
CY2013 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
179000
CY2012 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
43000
CY2013Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
20000
CY2012Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
19000
CY2012 us-gaap Line Of Credit Facility Commitment Fee Amount
LineOfCreditFacilityCommitmentFeeAmount
120000
CY2012 biol Line Of Credit Facility Aggregate Commitment Fee Amount
LineOfCreditFacilityAggregateCommitmentFeeAmount
240000
CY2013 biol Additional Commitment Fees And Legal Costs Incurred
AdditionalCommitmentFeesAndLegalCostsIncurred
67000
CY2013Q4 biol Financed Insurance Premium Payable
FinancedInsurancePremiumPayable
197000
CY2012Q4 biol Financed Insurance Premium Payable
FinancedInsurancePremiumPayable
379000
CY2013 us-gaap Short Term Debt Description
ShortTermDebtDescription
Nine
CY2013 us-gaap Interest Expense Other
InterestExpenseOther
5000
CY2012 us-gaap Interest Expense Other
InterestExpenseOther
5000
CY2011 us-gaap Interest Expense Other
InterestExpenseOther
5000
CY2013Q4 biol Financed Insurance Premium Finance Charge
FinancedInsurancePremiumFinanceCharge
0.029
CY2012Q4 biol Financed Insurance Premium Finance Charge
FinancedInsurancePremiumFinanceCharge
0.030
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-138000
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
31000
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
18000
CY2011 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
16000
CY2013 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-27000
CY2012 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
32000
CY2011 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
20000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-134000
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
50000
CY2011 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
36000
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
72000
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
57000
CY2011 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
66000
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-118000
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.130
CY2011 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.023
CY2013 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.009
CY2012 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0.162
CY2011 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0.020
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
12000
CY2011 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-16000
CY2013 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
16000
CY2012 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-8000
CY2011 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
3000
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.340
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.340
CY2011 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.340
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.270
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.282
CY2011 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.202
CY2013 us-gaap Effective Income Tax Rate Reconciliation Deductions Other
EffectiveIncomeTaxRateReconciliationDeductionsOther
-0.031
CY2012 us-gaap Effective Income Tax Rate Reconciliation Deductions Other
EffectiveIncomeTaxRateReconciliationDeductionsOther
-0.037
CY2011 us-gaap Effective Income Tax Rate Reconciliation Deductions Other
EffectiveIncomeTaxRateReconciliationDeductionsOther
-0.023
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.042
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.041
CY2011 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.181
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.021
CY2011 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.030
CY2013 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.002
CY2012 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.006
CY2011 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.002
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.016
CY2012 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.061
CY2011 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.038
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.142
CY2013 biol Effective Income Tax Rate Reconciliation Other Reconciling Items
EffectiveIncomeTaxRateReconciliationOtherReconcilingItems
0.003
CY2012 biol Effective Income Tax Rate Reconciliation Other Reconciling Items
EffectiveIncomeTaxRateReconciliationOtherReconcilingItems
0.005
CY2011 biol Effective Income Tax Rate Reconciliation Other Reconciling Items
EffectiveIncomeTaxRateReconciliationOtherReconcilingItems
-0.003
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.014
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.038
CY2011 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.020
CY2013Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
283000
CY2012Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
405000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
1702000
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
2082000
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
8000
CY2012Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
328000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2565000
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2348000
CY2013Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
7000
CY2012Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
45000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1583000
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1167000
CY2013Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
871000
CY2012Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
868000
CY2013Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
376000
CY2012Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
240000
CY2013Q4 us-gaap Deferred Tax Assets Other Comprehensive Loss
DeferredTaxAssetsOtherComprehensiveLoss
109000
CY2012Q4 us-gaap Deferred Tax Assets Other Comprehensive Loss
DeferredTaxAssetsOtherComprehensiveLoss
127000
CY2013Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
142000
CY2012Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
160000
CY2011 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.08
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
28058000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25746000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35704000
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33516000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35566000
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
33341000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
138000
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
175000
CY2013Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
696000
CY2012Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
703000
CY2013Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
59000
CY2012Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
119000
CY2013Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
755000
CY2012Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
822000
CY2013Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
617000
CY2012Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
647000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1226000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
CY2013 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
658000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
568000
CY2013 biol Reversal Deferred Tax Liability Expirations
ReversalDeferredTaxLiabilityExpirations
138000
CY2013 biol Recognized Previously Deferred Tax Assets
RecognizedPreviouslyDeferredTaxAssets
107000
CY2013 biol Tax Benefits Recognized During Period
TaxBenefitsRecognizedDuringPeriod
245000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
77900000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
55200000
CY2013 biol Unrecognized Tax Benefits That Would Impact Additional Paid In Capital
UnrecognizedTaxBenefitsThatWouldImpactAdditionalPaidInCapital
7000000
CY2013Q4 biol Unrecognized Tax Benefits Impact Additional Paid In Capital If Realized
UnrecognizedTaxBenefitsImpactAdditionalPaidInCapitalIfRealized
2700000
CY2013Q4 biol Valuation Allowance State Dta
ValuationAllowanceStateDta
1.00
CY2006Q1 biol Lease Term
LeaseTerm
P5Y
CY2006Q1 biol Lease Facility Area
LeaseFacilityArea
57000
CY2006Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
38692
CY2009Q3 biol Period For Extended Lease
PeriodForExtendedLease
2015-04-20
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1100000
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
789000
CY2011 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2013Q4 biol Change In Control Employee Severance
ChangeInControlEmployeeSeverance
717000
CY2013Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
11400000
CY2013 us-gaap Legal Fees
LegalFees
250000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
697000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
901000
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4130000
CY2011 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
657000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
766000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3858000
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
214000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
966000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3860000
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
343000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
765000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4441000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2688000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
90000
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.60
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y2M1D
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.92
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.75
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.12
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.63
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.48
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.07
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.23
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.51
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.51
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
11.24
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y9M29D
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1574000
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1343000
CY2013Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
4441000
CY2013Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.51
CY2013 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P3Y9M29D
CY2013Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
2688000
CY2013Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
3.51
CY2013 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
CY2012 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
CY2011 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
860000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
91000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1328000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.82
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.39
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.97
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue
1544000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue
1737000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue
1259000
CY2013Q3 biol Maximum Stock Offering Price
MaximumStockOfferingPrice
5000000
CY2013Q4 biol Special Stock Dividends Declared
SpecialStockDividendsDeclared
0.0050
CY2013Q3 biol Special Stock Dividends Declared
SpecialStockDividendsDeclared
0.0050
CY2013Q2 biol Special Stock Dividends Declared
SpecialStockDividendsDeclared
0.0050
CY2013Q1 biol Special Stock Dividends Declared
SpecialStockDividendsDeclared
0.0050
CY2011Q3 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
2000000
CY2012 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
1.73
CY2011 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
2.68
CY2013 biol Sales To Customers Located Within United States
SalesToCustomersLocatedWithinUnitedStates
0.63
CY2012 biol Sales To Customers Located Within United States
SalesToCustomersLocatedWithinUnitedStates
0.71
CY2011 biol Sales To Customers Located Within United States
SalesToCustomersLocatedWithinUnitedStates
0.67
CY2013 biol Sales To Customers Located Outside Of United States
SalesToCustomersLocatedOutsideOfUnitedStates
0.37
CY2012 biol Sales To Customers Located Outside Of United States
SalesToCustomersLocatedOutsideOfUnitedStates
0.29
CY2011 biol Sales To Customers Located Outside Of United States
SalesToCustomersLocatedOutsideOfUnitedStates
0.33
CY2013 biol No Individual Country Other Than United States Represents More Than Ten Percentage Of Net Revenue
NoIndividualCountryOtherThanUnitedStatesRepresentsMoreThanTenPercentageOfNetRevenue
No individual international country represented more than 10% of net revenue
CY2012 biol No Individual Country Other Than United States Represents More Than Ten Percentage Of Net Revenue
NoIndividualCountryOtherThanUnitedStatesRepresentsMoreThanTenPercentageOfNetRevenue
No individual international country represented more than 10% of net revenue
CY2011 biol No Individual Country Other Than United States Represents More Than Ten Percentage Of Net Revenue
NoIndividualCountryOtherThanUnitedStatesRepresentsMoreThanTenPercentageOfNetRevenue
No individual international country represented more than 10% of net revenue
CY2013 us-gaap Entity Wide Revenue Major Customer Percentage
EntityWideRevenueMajorCustomerPercentage
0.05
CY2012 us-gaap Entity Wide Revenue Major Customer Percentage
EntityWideRevenueMajorCustomerPercentage
0.03
CY2011 us-gaap Entity Wide Revenue Major Customer Percentage
EntityWideRevenueMajorCustomerPercentage
0.19
CY2013 us-gaap Concentration Risk Customer
ConcentrationRiskCustomer
Less than 10%
CY2012 us-gaap Concentration Risk Customer
ConcentrationRiskCustomer
Less than 10%
CY2013 biol Entity Wide Accounts Receivable Major Customer Number
EntityWideAccountsReceivableMajorCustomerNumber
0
CY2012 biol Entity Wide Accounts Receivable Major Customer Number
EntityWideAccountsReceivableMajorCustomerNumber
0

Files In Submission

Name View Source Status
0001564590-14-000856-index-headers.html Edgar Link pending
0001564590-14-000856-index.html Edgar Link pending
0001564590-14-000856.txt Edgar Link pending
0001564590-14-000856-xbrl.zip Edgar Link pending
biol-10k_20131231.htm Edgar Link pending
biol-20131231.xml Edgar Link completed
biol-20131231.xsd Edgar Link pending
biol-20131231_cal.xml Edgar Link unprocessable
biol-20131231_def.xml Edgar Link unprocessable
biol-20131231_lab.xml Edgar Link unprocessable
biol-20131231_pre.xml Edgar Link unprocessable
biol-ex10_201312311278.htm Edgar Link pending
biol-ex21_201312311279.htm Edgar Link pending
biol-ex23_201312311280.htm Edgar Link pending
biol-ex31_201312311281.htm Edgar Link pending
biol-ex31_201312311282.htm Edgar Link pending
biol-ex32_201312311283.htm Edgar Link pending
biol-ex32_201312311284.htm Edgar Link pending
biol-ex4_201312311546.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g20140317192131271317.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending